GCM
FDMT icon

Graham Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Graham Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43,080
Closed -$139K – 1386
2025
Q1 		$139K Buy
+43,080
New +$203K ﹤0.01% 1176
2024
Q4 		– Sell
-19,773
Closed -$214K – 1310
2024
Q3 		$214K Buy
19,773
+5,124
+35% +$85K ﹤0.01% 889
2024
Q2 		$307K Buy
+14,649
New +$367K 0.01% 724

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's FDMT Position: Q2 2025 in Review

Graham Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 43,080 shares — an estimated $139K sold.

Graham Capital Management first reported a position in FDMT in Q2 2024 and held it in 3 quarters. The position peaked at $307K in Q2 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • Graham Capital Management reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 43,080 4D Molecular Therapeutics shares in Q2 2025, an estimated $139K.
  • Graham Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 3 quarters.
  • Graham Capital Management's 4D Molecular Therapeutics position peaked at $307K in Q2 2024.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.